Literature DB >> 21930466

Bifurcation Optimisation Stent System (BiOSS Lim) with sirolimus elution: results from porcine coronary artery model.

Dobrin Vassilev1, Robert Gil, Krzysztof Milewski.   

Abstract

AIMS: The optimal treatment strategy for coronary bifurcation lesions is still unknown. The BiOSS Lim stents (Bifurcation Optimisation Stent System) is a novel dedicated bifurcation stent introduced over a single wire in to the main vessel, covered with biodegradable polymer and sirolimus. It has wider proximal and narrower distal parts. The aim of the study was to assess applicability of the the BiOSS Lim stent in a porcine coronary model. METHODS AND
RESULTS: A total of 14 BiOSS Lims were implanted in normal non-atherosclerotic porcine coronary bifurcations of 14 animals (six stents for 28 days, eight stents for 90 days) using 1.1:1.0 stent-to-artery ratio. Stent geometry and morphology were evaluated by Faxitron imagery (Faxitron Bioptics, LLC, IL, USA). Vascular effects were assessed based on angiographic and histological analysis. Analysis of Faxitron images revealed no major abnormalities except two struts fractures at the place of connection between the mid-portion and proximal wider part of the stent. Histomorphometry showed decreased area stenosis and intimal thickness at 90 days compared with the 28 days cohort. The inflammatory scores were low (<1) at both time points and struts endothelialisation was completed at 28 days.
CONCLUSIONS: The novel BiOSS Lim stent demonstrates good short- and mid-term vascular effects in a porcine coronary bifurcation model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930466     DOI: 10.4244/EIJV7I5A98

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  4 in total

1.  Dedicated Bifurcation Drug-eluting Stent BiOSS® - A Novel Device for Coronary Bifurcation Treatment.

Authors:  Robert J Gil; Dobrin Vassilev; Jacek Bil
Journal:  Interv Cardiol       Date:  2013-03

2.  Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent.

Authors:  Robert J Gil; Tomasz Pawłowski; Jacek Legutko; Maciej Lesiak; Adam Witkowski; Mariusz Gąsior; Adam Kern; Jacek Bil
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

3.  Comparative analysis of lumen enlargement mechanisms achieved with the bifurcation dedicated BiOSS) stent versus classical coronary stent implantations by means of provisional side branch stenting strategy: an intravascular ultrasound study.

Authors:  Robert J Gil; Jacek Bil; Aleksandra Michałek; Dobrin Vassiliev; Ricardo A Costa
Journal:  Int J Cardiovasc Imaging       Date:  2013-07-19       Impact factor: 2.357

4.  Treatment of a Coronary Bifurcation Lesion Using One Dedicated Sirolimus Eluting Bifurcation Stent in Combination with a Bioresorbable Vascular Scaffold: A Novel Option for Coronary Bifurcation Approach.

Authors:  Javier Benezet; Antonio Agarrado; Jesús Oneto
Journal:  Case Rep Cardiol       Date:  2016-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.